High-Resolution Breast Ultrasound May Reduce Biopsies
September 1st 1999NEW ORLEANS-High-resolution ultrasound provides additional information about mammographically identified malignant calcifications and may find malignancies unseen on mammography, Beverly E. Hashimoto, MD, said at the annual meeting of the American Roentgen Ray Society.
Virtual Endoscopy: An Innovation in GI Tract Imaging
September 1st 1999NEW ORLEANS-Virtual endoscopy of the gastrointestinal tract is a rapidly advancing technology, Bradford J. Wood, MD, said in an interview with Oncology News International. “Radiologists should become familiar with the virtual endoscopic appearance of a variety of GI pathologies so that they can speak a common language with surgical and gastrointestinal endoscopists,” he said.
US-Guided FNA Cost-Effective Diagnostic Tool for Finding Nonpalpable Breast Lesions
September 1st 1999NEW ORLEANS-In selected patients with radiographically identified nonpalpable breast abnormalities, ultrasound-guided fine-needle aspiration (FNA) with follow-up mammograms is effective and offers a cost savings over stereotactic mammotomy (directional vacuum-assisted breast biopsy). S.S. Buchbinder, MD, of the Department of Radiology, Albert Einstein College of Medicine, New York, reported the results at the American Roentgen Ray Society annual meeting.
Dose-Intense Chemo Regimen for Younger Patients With NHL
September 1st 1999LUGANO, Switzerland-Younger patients with histologically aggressive, stage IV non-Hodgkin’s lymphoma (NHL) might benefit from a dose-intense etoposide-containing regimen, according to late follow-up results from the British National Lymphoma Investigation (BNLI) reported at the VII International Conference on Malignant Lymphoma.
FTC Wants Health Warning Labels on Cigars and Ad Ban
September 1st 1999WASHINGTON-What’s good for regulating cigarettes is equally good for cigars, the Federal Trade Commission (FTC) argued in a new report to Congress. It recommended that Congress require health warning labels for cigars, ban all cigar advertising on radio and television, and enact measures to restrict the access of underage smokers to cigars.
Book Review:Nutritional Oncology
September 1st 1999Nutritional Oncology provides acomprehensive review of the current scientific literature on nutritional factors affecting the prevention and treatment of cancer. The book’s primary objective is to detail findings in the new field of nutritional oncology,
Scientists Warn About Potential Misuse of Gene Therapy
September 1st 1999Scientists fear that existing genetic techniques will be misused before the consequences of altering the human blueprint on personal, generational, and societal levels are fully realized. At St. Jude Children’s Research Hospital in Memphis, Tennessee,
Diagnosis and Treatment of Depression in Cancer Patients
September 1st 1999Drs. Pirl and Roth describe various problems that complicate efforts to accurately diagnose and appropriately treat depression in cancer patients. These include the subjective nature of symptoms, multiple possible diagnoses within the spectrum of mood
Diagnosis and Treatment of Depression in Cancer Patients
September 1st 1999Pirl and Roth synthesize well the rich literature that now exists on the prevalence, causes, and treatment of depression in patients with cancer. Their review focuses attention on: (1) those factors-patient- as well as disease- and treatment-related
One Year Later, Its President Assesses The March’s Impact
September 1st 1999WASHINGTON-Last year, tens of thousands gathered on The Mall in front of the US Capitol and in scores of communities nationwide to urge the federal government to make cancer the number one medical research priority. On Sept. 25, a candlelight vigil in front of the Lincoln Memorial will mark the first anniversary of that event, known as The March.
Stereotactic Core Biopsy Establishes Many Prognostic Factors
August 1st 1999NEW ORLEANS-For the majority of mammographically detected invasive carcinomas with a mean size of 11 mm, stereotactic biopsy obtained with larger gauge needles provides adequate material for establishing a host of prognostic factors, said Michael D. Lagios, MD, medical director of the Breast Cancer Consultation Service, St. Mary’s Medical Center, San Francisco.
NCI Discovers Gene Variations From Existing Databases
August 1st 1999BETHESDA, Md-Using new computer software to “mine” existing databases, National Cancer Institute (NCI) scientists have discovered 10,435 possible new variations in human genes. The so-called single nucleotide polymorphisms, or SNPs, must still be validated, but NCI said each of the variations met statistical confidence levels of 0.99%.
Going Beyond CHOP in Advanced Large-Cell Lymphoma
August 1st 1999LUGANO, Switzerland-Although a decade’s worth of phase II studies in advanced large-cell lymphoma have suggested that new, multidrug regimens could nearly double both the complete response rate and the proportion of long-term survivors, appearances can be deceiving, Richard Fisher, MD, Coleman Professor of Oncology, Loyola University Medical Center, Maywood, Illinois, said at the VII International Conference on Malignant Lymphoma.
Memorial Sloan-Kettering Opens Rockefeller Outpatient Pavilion
August 1st 1999NEW YORK-Memorial Sloan-Kettering Cancer Center’s new Laurance S. Rockefeller Outpatient Pavilion provides advanced programs for outpatient cancer diagnosis and treatment in a calm and beautiful environment. “We believe this facility will serve as a national model for the delivery of outpatient cancer care in the new millennium,” said Paul A. Marks, MD, president and CEO.
AHCPR Plans Health Care Market, Managed Care Research Centers
August 1st 1999ROCKVILLE, Md-The Agency for Health Care Policy Research (AHCPR) plans to spend up to $11 million to fund two or three research centers to conduct studies of the health care market and managed care. The aim is to help policy makers understand, monitor, and anticipate how changes in the nation’s market-driven health care system affect costs, access to services, and quality of care. Interested researchers have until Sept. 2 , 1999, to submit letters of intent.
NSAIDs May Protect Against Common GI Cancers
August 1st 1999ORLANDO-“Nonsteroidal anti-inflammatory drugs (NSAIDs) confer protection against the common GI cancers, not only against colon and rectal cancer, which we’ve known about, but also in the esophagus and stomach, where the protection was at least as strong,” Michael Langman, MD, said at the Digestive Disease Week meeting.
City of Hope Receives $36 Million for State-of-the-Art Hospital
August 1st 1999The City of Hope National Medical Center and Beckman Research Institute received the largest individual gift in the cancer center’s 86-year history from Irwin Helford, chairman of Viking Office Products and vice chairman of Office Depot. The
Anal Condylomata More Threatening in HIV+ Patients
August 1st 1999ORLANDO-A French study is “the first to quantify the frequency of anal cancer in HIV patients,” Iradj Sobhani, MD, said at the Digestive Disease Week meeting. “Anal carcinoma is rare in the general population, but relatively common in HIV-positive patients,” said Dr. Sobhani, of the Gastroenterology Service, Hopital Bichat, Paris.
IOM Finds No Link Between Silicone Implants and Cancer
August 1st 1999WASHINGTON-An extensive review of the medical literature finds that women with silicone breast implants are no more likely to develop cancer and several other major ailments than women in the general population. The new report by the Institute of Medicine (IOM) concludes, however, that implants commonly lead to often-painful complications that may require surgery or other treatment.
IL-12 Gene Therapy Inhibits Osteosarcoma Lung Mets in Mice
August 1st 1999PHILADELPHIA-Intranasal delivery of an adenoviral vector containing the murine interleukin-12 (IL-12) gene has been shown to inhibit osteosarcoma lung metastases in mice. IL-12 is a molecule that activates the immune system and has recently been shown to have antiangiogenic activity. “Our hypothesis is that IL-12 interfered with tumor angiogenesis,” Laura L. Worth, MD, PhD, said at the annual meeting of the American Association for Cancer Research.
Law May Play an Important Role in End of Life Decisions
August 1st 1999NEW YORK- The law “need not be a barrier to good decisions at the end of life,” Carl H. Coleman, JD, executive director of the New York State Task Force on Life and the Law, said at a panel discussion on legal issues and end of life care sponsored by the Association of the Bar of the City of New York.
No Advantage to Extended-Field Irradiation in Advanced HD
August 1st 1999LUGANO, Switzerland-The impact of radiotherapy on disease control and toxicity in patients with advanced Hodgkin’s disease remains controversial. In fact, a 1998 meta-analysis suggested that combined-modality therapy results in worse long-term survival than does chemotherapy alone.
Hybrid Chemotherapy Boosts Survival Time in Advanced HD
August 1st 1999LUGANO, Switzerland-ChlVPP/EVA hybrid chemotherapy proved more effective than both MVPP and VAPEC-B as first-line treatment for advanced Hodgkin’s disease (HD) in two collaborative studies, Dr. John A. Radford, of Christie Hospital, Manchester, UK, reported at the VII International Conference on Malignant Lymphoma. The hybrid regimen consists of chlorambucil, vinblastine, procarbazine, and prednisone plus etoposide, vincristine, and doxorubicin (Adriamycin).
Doxil Approved for Refractory Metastatic Ovarian Cancer
August 1st 1999ROCKVILLE, Md-Doxil (doxorubicin HCl liposome injection, ALZA Corporation) has won accelerated FDA approval of its supplemental New Drug Application for the treatment of metastatic ovarian cancer refractory to both paclitaxel (Taxol)- and platinum-based chemotherapy regimens. Accelerated approval requires the company to conduct additional research to demonstrate that the drug is associated with clinical benefit. Doxil, a liposomal formulation of doxorubicin, is currently approved for use in AIDS-related Kaposi’s sarcoma.
Viral Mouthwash Kills Cells That Lack Normal p53
August 1st 1999ATLANTA-Mouthwash containing a modified virus that kills cells lacking p53 (a common deletion in many cancerous and precancerous lesions) may prevent development of invasive squamous cell head and neck cancers in smokers, researchers reported at the annual meeting of the American Society of Clinical Oncology.
Evidence for EMF-Cancer Link Deemed Weak, Risk Small
August 1st 1999RESEARCH TRIANGLE PARK, NC-After 6 years of research and 2 years of review, the National Institute of Environmental Health Sciences reported to Congress that the evidence that low-frequency electromagnetic fields (EMFs) can cause cancer and other human diseases is weak, but added that EMF exposure “cannot be recognized as entirely safe.”
Gillette Company Launches Women’s Cancer Connection
August 1st 1999NEW YORK-The Gillette Company has launched an initiative called The Gillette Women’s Cancer Connection to provide emotional support to cancer patients and their families. The program is specifically targeted at women with breast or gynecologic cancer.